succinobucol has been researched along with Coronary Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L | 1 |
| Veryard, C | 1 |
| Tanimoto, T | 1 |
| Dart, AM; Duffy, SJ | 1 |
1 review(s) available for succinobucol and Coronary Disease
| Article | Year |
|---|---|
[Research and developmental strategy of anti-dyslipidemic agents].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Disease Models, Animal; Drug Design; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Oligoribonucleotides, Antisense; Probucol; Receptors, G-Protein-Coupled; Receptors, Nicotinic | 2007 |
2 trial(s) available for succinobucol and Coronary Disease
| Article | Year |
|---|---|
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary Disease; Coronary Restenosis; Coronary Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Probucol; Stents; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2003 |
Novel cardiac therapies and innocent by standers.
Topics: Antioxidants; Coronary Disease; Double-Blind Method; Humans; Probucol | 2008 |
1 other study(ies) available for succinobucol and Coronary Disease
| Article | Year |
|---|---|
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Erythropoietin; Extremities; Fibroblast Growth Factor 2; Humans; Ischemia; Lipid Metabolism Disorders; Myocardial Infarction; Niacin; Probucol | 2007 |